The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

Launched by SUN YAT-SEN UNIVERSITY · Sep 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with recurrent hepatocellular carcinoma (HCC), which is a type of liver cancer that has come back after initial treatment. The trial compares two treatment options: one group will receive a combination of transarterial chemoembolization (TACE) and a medication called Lenvatinib, while the other group will get the same treatments plus a procedure called ablation, which helps to destroy cancer cells directly. Researchers want to see if adding ablation will improve the outcomes for patients with intermediate-stage recurrent HCC.

To participate in this trial, patients need to be between 18 and 75 years old and have been diagnosed with recurrent HCC that is considered intermediate-stage. This means they have two to three tumors, with at least one being larger than 3 cm, and no more than six tumors total. Patients must also have good liver function and a life expectancy of more than three months. Those who join the trial can expect to receive close monitoring and care throughout the study. It's important to remember that this research is aimed at finding better treatment options for liver cancer, and participation will help contribute to important medical knowledge.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18-75 years;
• • 2. RHCC diagnosed by imaging;
• • 3. intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors);
• • 4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
• • 5. absence of extrahepatic metastasis or macrovascular invasion;
• • 6. Child-Pugh class A or B;
• • 7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.
• • 8. life expectance \>3 months;
• Exclusion Criteria:
• • 1. under 18 years or over 75 years of age;
• • 2. primary intermediate-stage HCC;
• • 3. RHCC with more than six tumors, or single RHCC
• • (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;